...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in endocrinology, diabetes, and obesity >The promise of apolipoprotein A-I mimetics.
【24h】

The promise of apolipoprotein A-I mimetics.

机译：载脂蛋白A-I模拟物的前景。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Synthetic high-density lipoprotein (HDL) and apolipoprotein (apo) A-I mimetic peptides emulate many of the atheroprotective biological functions attributed to HDL and can modify atherosclerotic disease processes. Administration of these agents as HDL replacement or modifying therapy has tremendous potential of providing new treatments for cardiovascular disease. Progress in the understanding of these agents is discussed in this review. RECENT FINDINGS: Prospective, observational, and interventional studies have convincingly demonstrated that elevated serum levels of high-density lipoprotein-cholesterol (HDL-C) are associated with reduced risk for coronary heart disease (CHD). Although traditional pharmacological agents have shown modest utility in raising HDL levels and reducing CHD risk, use of HDL and apo A-I mimetics provides novel therapies to not only increase HDL levels, but to also influence HDL functionality. Evidence developed over the last several years has identified a number of pathways affected by synthetic HDL and apoA-I mimetic peptides, including enhancing reverse cholesterol transport and reducing oxidation and inflammation that directly influence the progression and regression of atherosclerotic disease. SUMMARY: Clinical trials of relatively short-term synthetic HDL infusion into patients with CHD demonstrate beneficial effects. Use of apo A-I mimetic peptides could potentially overcome some of the limitations associated with use of the intact apo. Studies to establish the most efficacious peptides, optimal dosing regimens, and routes of administration are needed. Use of apo A-I mimetic peptides shows great promise as a therapeutic modality for HDL replacement and enhancing HDL function in treatment of patients with CHD.
机译：审查目的：合成的高密度脂蛋白（HDL）和载脂蛋白（apo）A-I模拟肽可模拟归因于HDL的许多动脉粥样硬化生物学功能，并且可以改变动脉粥样硬化疾病的进程。这些药物作为HDL替代疗法或改良疗法的应用，具有为心血管疾病提供新疗法的巨大潜力。在这篇评论中讨论了对这些代理的理解方面的进展。最近的发现：前瞻性，观察性和干预性研究令人信服地证明，血清高密度脂蛋白胆固醇（HDL-C）水平升高与冠心病（CHD）风险降低相关。尽管传统药物在提高HDL水平和降低CHD风险方面显示出适度的效用，但是HDL和apo A-I模拟物的使用提供了新颖的疗法，不仅可以提高HDL水平，而且可以影响HDL功能。过去几年的证据表明，许多途径都受到合成HDL和apoA-I模拟肽的影响，包括增强胆固醇逆向转运，减少直接影响动脉粥样硬化疾病进展和消退的氧化和炎症。简介：对CHD患者进行相对短期合成HDL输注的临床试验显示出有益的效果。使用载脂蛋白A-I模拟肽可以潜在地克服与使用完整载脂蛋白相关的一些限制。需要进行研究以建立最有效的肽，最佳给药方案和给药途径。载脂蛋白A-I模拟肽的使用显示出巨大的希望，作为用于CHD患者的HDL替代和增强HDL功能的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号